MedPath

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

Registration Number
NCT01992653
Lead Sponsor
Genentech, Inc.
Brief Summary

This multicenter, open-label, dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of polatuzumab vedotin in combination with rituximab or obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (CHP chemotherapy) in participants with non-Hodgkin's lymphoma (NHL). Participants will receive escalating doses of polatuzumab vedotin intravenously (IV) every 3 weeks in combination with standard doses of rituximab plus CHP chemotherapy (R-CHP) or obinutuzumab plus CHP chemotherapy (G-CHP). Participants will be treated for a total of six or eight cycles in accordance with local institutional practice. Two parallel treatment arms will explore doses of polatuzumab vedotin in combination with R-CHP or G-CHP. The maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of polatuzumab vedotin in combination with R-CHP will be identified before it is combined with G-CHP. Once the MTD or RP2D is determined, polatuzumab vedotin will be dosed at MTD or RP2D -1 in combination with G-CHP to start the dose escalation of this combination.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
85
Inclusion Criteria

All Participants:

  • At least one bi-dimensionally measurable lesion, defined as greater than (>) 1.5 centimeters (cm) in its longest dimension
  • Life expectancy of at least 24 weeks
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Adequate hematologic function (unless inadequate function is due to underlying disease, as established by extensive bone marrow involvement or is due to hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator)
  • Agreement to use highly effective contraception measures. Women of childbearing potential must agree to remain abstinent or use contraceptive measures that result in a failure rate of <1 percent (%) per year during the treatment period and for at least 12 months for R-CHP arm or for at least 18 months for G-CHP arm after the last dose of study drug. Men must agree to remain abstinent or to use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 5 months after the last dose of study drug

Dose-Escalation Portion of the Study:

  • Histologically confirmed B-cell NHL: Participants with newly diagnosed B-cell NHL or relapsed/refractory B-cell NHL are eligible
  • No more than one prior systemic treatment regimen for B-cell NHL (single agent anti-cluster of differentiation [CD] 20 monoclonal antibody therapy will not be counted as a prior treatment regimen)
  • No prior treatment with anthracyclines

Expansion Portion of the Study:

  • Previously untreated participants with diffuse large B-cell lymphoma (DLBCL)
  • International Prognostic Index (IPI) score of 2-5
Exclusion Criteria

Dose-Escalation Portion of the Study:

  • Diagnosis of primary mediastinal DLBCL

Expansion Portion of the Study:

  • Participants with transformed lymphoma
  • Prior therapy for NHL

All Participants:

  • Prior stem cell transplant
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
  • Contraindication to receive any of the individual components of R-CHP or G-CHP
  • Current Grade greater than (>) 1 peripheral neuropathy
  • Ongoing corticosteroid use of >30 milligrams per day (mg/day) of prednisone/prednisolone or equivalent. Participants receiving corticosteroid treatment with less than or equal to (</=) 30 mg/day of prednisone/prednisolone or equivalent must be documented to be on a stable dose of at least 4 weeks' duration before Cycle 1 Day 1
  • Primary central nervous system (CNS) lymphoma
  • Vaccination with live vaccines within 6 months before Cycle 1 Day 1
  • History of other malignancy that could affect compliance with the protocol or interpretation of results. Participants with a history of curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix are eligible. Participants with a malignancy that has been treated with surgery alone with curative intent will also be excluded unless the malignancy has been in documented remission without treatment for greater than or equal to (</=) 5 years before enrollment
  • Evidence of significant, uncontrolled concomitant diseases, including renal disease that would preclude chemotherapy administration, or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
  • Significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, congestive heart failure, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks before Cycle 1 Day 1
  • Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  • Positive for hepatitis B or hepatitis C infection
  • Prior radiotherapy to the mediastinal/pericardial region
  • Pregnant or lactating women
  • Recent major surgery within 6 weeks before the start of Cycle 1 Day 1

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Polatuzumab Vedotin (1.4mg) + G-CHPCyclophosphamideDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Polatuzumab Vedotin (1.4mg) + G-CHPObinutuzumabDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Polatuzumab Vedotin (1.4mg) + G-CHPDoxorubicinDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Polatuzumab Vedotin (1.4mg) + G-CHPPolatuzumab VedotinDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Polatuzumab Vedotin (1.4mg) + G-CHPPrednisoloneDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Polatuzumab Vedotin (1.0mg) + R-CHPDoxorubicinDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.4mg) + G-CHPPrednisoneDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Polatuzumab Vedotin (1.0mg) + R-CHPCyclophosphamideDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.0mg) + R-CHPPolatuzumab VedotinDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.0mg) + R-CHPPrednisoloneDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.8mg) + G-CHPPrednisoneDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Polatuzumab Vedotin (1.0mg) + R-CHPPrednisoneDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.0mg) + R-CHPRituximabDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.8mg) + G-CHPCyclophosphamideDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Polatuzumab Vedotin (1.8mg) + G-CHPObinutuzumabDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Polatuzumab Vedotin (1.8mg) + G-CHPDoxorubicinDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Polatuzumab Vedotin (1.8mg) + G-CHPPrednisoloneDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Polatuzumab Vedotin (1.8mg) + G-CHPPolatuzumab VedotinDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Polatuzumab Vedotin (1.4mg) + R-CHPCyclophosphamideDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.4mg) + R-CHPDoxorubicinDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.4mg) + R-CHPPrednisoloneDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.4mg) + R-CHPPolatuzumab VedotinDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.4mg) + R-CHPPrednisoneDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.4mg) + R-CHPRituximabDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.8mg) + R-CHPDoxorubicinDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.8mg) + R-CHPCyclophosphamideDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.8mg) + R-CHPPolatuzumab VedotinDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.8mg) + R-CHPPrednisoloneDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.8mg) + R-CHPPrednisoneDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (2.4mg) + R-CHPCyclophosphamideDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (1.8mg) + R-CHPRituximabDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (2.4mg) + R-CHPPolatuzumab VedotinDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (2.4mg) + R-CHPDoxorubicinDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (2.4mg) + R-CHPPrednisoloneDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Expansion: Polatuzumab Vedotin (1.8mg) + R-CHPCyclophosphamideDose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (2.4mg) + R-CHPPrednisoneDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Polatuzumab Vedotin (2.4mg) + R-CHPRituximabDose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Expansion: Polatuzumab Vedotin (1.8mg) + R-CHPDoxorubicinDose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Expansion: Polatuzumab Vedotin (1.8mg) + R-CHPPrednisoneDose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Expansion: Polatuzumab Vedotin (1.8mg) + R-CHPPolatuzumab VedotinDose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Expansion: Polatuzumab Vedotin (1.8mg) + R-CHPPrednisoloneDose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Expansion: Polatuzumab Vedotin (1.8mg) + R-CHPRituximabDose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
Expansion: Polatuzumab Vedotin (1.8mg) + G-CHPCyclophosphamideDose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Expansion: Polatuzumab Vedotin (1.8mg) + G-CHPDoxorubicinDose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Expansion: Polatuzumab Vedotin (1.8mg) + G-CHPObinutuzumabDose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Expansion: Polatuzumab Vedotin (1.8mg) + G-CHPPolatuzumab VedotinDose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Expansion: Polatuzumab Vedotin (1.8mg) + G-CHPPrednisoneDose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Expansion: Polatuzumab Vedotin (1.8mg) + G-CHPPrednisoloneDose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
Primary Outcome Measures
NameTimeMethod
Number of Participants With Adverse Events in Diffuse Large B-Cell Lymphoma (DLBCL) PopulationBaseline up to 5 years

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs).

Number of Participants With Adverse Events in Non-DLBCL PopulationBaseline up to 5 years

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs).

Number of Participants With Dose Limiting Toxicities (DLTs) in DLBCL PopulationCycle (Cy) 1 Day 1 (D1) to Cy 2 D1 (cycle length=21 days)

All dose-escalation cohorts will consist of at least 3 participants. If a DLT is observed in 1 participant at a given dose level during the DLT observation period before dose escalation, additional participants will be enrolled at that dose level for a total of at least 6 participants. DLT assessment forms part of determining the Maximum Tolerated Dose (MTD). The highest dose level resulting in DLTs in less than one-third of a minimum of 6 participants will be declared the MTD.

Number of Participants With DLTs in Non-DLBCL PopulationCycle (Cy) 1 Day 1 (D1) to Cy 2 D1 (cycle length=21 days)

All dose-escalation cohorts will consist of at least 3 participants. If a DLT is observed in 1 participant at a given dose level during the DLT observation period before dose escalation, additional participants will be enrolled at that dose level for a total of at least 6 participants. DLT assessment forms part of determining the Maximum Tolerated Dose (MTD). The highest dose level resulting in DLTs in less than one-third of a minimum of 6 participants will be declared the MTD.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants With Objective Response (CR or Partial Response [PR]), as Assessed by Investigator Using Cheson Criteria for DLBCL PopulationAt the end of treatment (Month 6)

Complete Response (CR) rate was defined as the percentage of participants with CR at the end of treatment, as assessed by the investigator, with and without FDG-PET. The overall response rate was defined as the percentage of participants with CR or PR at the end of treatment, as assessed by the investigator, with and without FDG-PET.

Percentage of Participants With Objective Response (CR or Partial Response [PR]), as Assessed by Investigator Using Cheson Criteria for Non-DLBCL PopulationAt the end of treatment (Month 6)

Complete Response (CR) rate was defined as the percentage of participants with CR at the end of treatment, as assessed by the investigator, with and without FDG-PET. The overall response rate was defined as the percentage of participants with CR or PR at the end of treatment, as assessed by the investigator, with and without FDG-PET.

Number of Participants With Anti-Polatuzumab Vedotin AntibodiesBaseline up to Month 9 (assessed prior to polatuzumab vedotin infusion [0 hour; Hr] on Day 2 [D2] of Cy 1 and 2, D1 of Cy 4, treatment completion/early termination [Month 6], and at 3 months post-treatment [Month 9]; cycle length=21 days)

The Anti-Drug Antibody (ADA) screening assay was optimized to tolerate drug interference and was able to detect 90 and 500 ng/mL of the positive control sample in the presence of 20 μg/mL of polatuzumab vedotin. Polatuzumab vedotin total antibody concentrations were determined for each ADA sample. Out of a total of 186 ADA samples that were measured for polatuzumab vedotin total antibody, 184 samples had levels less than 20 μg/mL. Polatuzumab vedotin total antibody concentrations ranged from \<0.050 μg/mL to 52.1 μg/mL with a median concentration of 3.38 μg/mL.

Number of Participants With Anti-Obinutuzumab AntibodiesBaseline up to Month 9 (assessed prior to obinutuzumab infusion [0 Hr] on D1 of Cy 1, 2, 4 and at 3 months post-treatment [Month 9]; cycle length=21 days)

The ADA screening assay was optimized to tolerate drug interference and was able to detect 500 ng/mL of the ADA-positive control sample in the presence of 50 micrograms/mL of obinutuzumab. Obinutuzumab concentrations were determined for each ADA sample. Out of a total of 48 ADA samples that were measured for obinutuzumab, 9 samples had levels less than 50 micrograms/mL of obinutuzumab. Obinutuzumab concentrations in ADA samples ranged from 0.282 micrograms/mL to 522 micrograms/mL with a median concentration of 210 micrograms/mL. Therefore, it is possible that samples with obinutuzumab concentrations greater than 50 micrograms/mL might be false negative for ADA.

Area Under the Concentration-Time Curve (AUC) of Polatuzumab VedotinPre-polatuzumab vedotin infusion (Hr 0), 30 minutes (min) post-infusion (infusion time=30-90 min) on D 2 of Cy 1, 2 & D1 of Cy 3, 4; Cy 1 Days 8 & 15; Cy 3 Day 8; at end of treatment (Month 6), at Month 3 follow-up (Month 9) (cycle length=21 days)

AUC information for Polatuzumab Vedotin was estimated from serum concentration data using non-compartmental analysis.

Maximum Concentration (Cmax) of Polatuzumab VedotinPre-polatuzumab vedotin infusion (Hr 0), 30 min post-infusion (infusion time=30-90 min) on D 2 of Cy 1, 2 & D1 of Cy 3, 4; Cy 1 Days 8 & 15; Cy 3 Day 8; at end of treatment (Month 6), at Month 3 follow-up (Month 9) (cycle length=21 days)

Cmax for Polatuzumab Vedotin was estimated from serum concentration data using non-compartmental analysis.

Clearance (CL) of Polatuzumab VedotinPre-polatuzumab vedotin infusion (Hr 0), 30 min post-infusion (infusion time=30-90 min) on D 2 of Cy 1, 2 & D1 of Cy 3, 4; Cy 1 Days 8 & 15; Cy 3 Day 8; at end of treatment (Month 6), at Month 3 follow-up (Month 9) (cycle length=21 days)

CL for Polatuzumab Vedotin was estimated from serum concentration data using non-compartmental analysis.

Terminal Half-Life (t1/2) of Polatuzumab VedotinPre-polatuzumab vedotin infusion (Hr 0), 30 min post-infusion (infusion time=30-90 min) on D 2 of Cy 1, 2 & D1 of Cy 3, 4; Cy 1 Days 8 & 15; Cy 3 Day 8; at end of treatment (Month 6), at Month 3 follow-up (Month 9) (cycle length=21 days)

t1/2 for Polatuzumab Vedotin was estimated from serum concentration data using non-compartmental analysis.

Steady-State Volume of Distribution (Vss) of Polatuzumab VedotinPre-polatuzumab vedotin infusion (Hr 0), 30 min post-infusion (infusion time=30-90 min) on D 2 of Cy 1, 2 & D1 of Cy 3, 4; Cy 1 Days 8 & 15; Cy 3 Day 8; at end of treatment (Month 6), at Month 3 follow-up (Month 9) (cycle length=21 days)

Vss for Polatuzumab Vedotin was estimated from serum concentration data using non-compartmental analysis.

Plasma Levels of CyclophosphamideEnd of cyclophosphamide infusion (infusion time=1-24 Hr), 3 and 23 hours post end of cyclophosphamide infusion on D1 of Cy 1 and 3 (cycle length=21 days)

Plasma levels of cyclophosphamide will be assessed and compared at the same timepoints of Cycle 1 (in the absence of polatuzumab vedotin) and Cycle 3 (in the presence of polatuzumab vedotin), and compared with historical data to evaluate potential PK interactions with polatuzumab vedotin.

Plasma Levels of Doxorubicin2, 24 hours post end of doxorubicin infusion (infusion time=15 min) on D1 of Cy 1 and 3 (cycle length=21 days)

Plasma levels of doxorubicin will be assessed and compared at the same timepoints of Cycle 1 (in the absence of polatuzumab vedotin) and Cycle 3 (in the presence of polatuzumab vedotin), and compared with historical data to evaluate potential PK interactions with polatuzumab vedotin.

Peripheral Neuropathy Symptom Severity: Therapy-Induced Neuropathy Assessment Scale (TINAS) Overall Neuropathy Severity ScoreWeekly up to Month 6 (22 weeks). TINAS data were collected daily, though for the analysis purpose for each participant, only the first record of each week was selected.

The TINAS is an 11-item questionnaire scored on a 0 to 10 scale, with 0 being the symptom is not present to 10 being the symptom is as bad as the participant can imagine. The questionnaire will be analyzed for the individual neuropathy symptoms experienced by a participant as well as the calculation of an overall neuropathy severity score. The TINAS scale will be completed daily over the course of study treatment. Additionally, to collect information about the reversibility of peripheral neuropathy, the TINAS will be completed once a week for the first 2 months, then once a month for the next 10 months following treatment completion. Results are only being reported here up until the End of Treatment visit (duration of Study treatment).

Peripheral Neuropathy Symptom Interference: TINAS Numbness/Tingling Item ScoreWeekly up to Month 6 (22 weeks). TINAS data were collected daily, though for the analysis purpose for each participant, only the first record of each week was selected.

The TINAS is an 11-item questionnaire scored on a 0 to 10 scale, with 0 being the symptom is not present to 10 being the symptom is as bad as the patient can imagine. The questionnaire will be analyzed for the individual neuropathy symptoms experienced by a participant as well as the calculation of an overall neuropathy severity score. The TINAS scale will be completed daily over the course of study treatment. Additionally, to collect information about the reversibility of peripheral neuropathy, the TINAS will be completed once a week for the first 2 months, then once a month for the next 10 months following treatment completion. Additionally, a single item that asks patients to rate when numbness and tingling was at the worst will be used to predict the onset of peripheral neuropathy. The measure takes less than 5 minutes to complete. Results are only being reported here up until the End of Treatment visit (duration of Study treatment).

Duration of Response, as Assessed by Investigator Using Cheson Criteria for DLBCL PopulationScreening up to disease progression or death, whichever occurs first (up to approximately 2.75 years)

Time from the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse or death from any cause (PFS), as assessed by the investigator for the subgroup of participants with a best overall response of CR or PR. For participants achieving a response who did not experience disease progression, relapse, or died prior to the time of the analysis, the DOR was censored on the date of last disease assessment.

Event Free Survival, as Assessed by Investigator Using Cheson Criteria for DLBCL PopulationScreening up to disease progression or death, whichever occurs first (up to approximately 2.75 years)

Time from randomization to disease progression or relapse, as assessed by the investigator, death from any cause, or initiation of any new anti-lymphoma therapy (NALT). If the specified event (disease progression or relapse, death, initiation of a NALT) did not occur, EFS was censored at the date of last tumor assessment. For participants without an event who did not have post-baseline tumor assessments, EFS was censored at the time of randomization.

Event Free Survival, as Assessed by Investigator Using Cheson Criteria for Non-DLBCL PopulationScreening up to disease progression or death, whichever occurs first (up to approximately 2.75 years)

Time from randomization to disease progression or relapse, as assessed by the investigator, death from any cause, or initiation of any new anti-lymphoma therapy (NALT). If the specified event (disease progression or relapse, death, initiation of a NALT) did not occur, EFS was censored at the date of last tumor assessment. For participants without an event who did not have post-baseline tumor assessments, EFS was censored at the time of randomization.

Relative Dose Intensity of Polatuzumab Vedotin (Ratio of the Amount of Drug Actually Administered to the Amount Planned) for DLBCL Population6 months

Relative dose intensity (DI) was defined as the ratio of the amount of a drug actually administered (actual DI) to the amount planned (planned DI) for a fixed time period, expressed as a percentage.

Duration of Response, as Assessed by Investigator Using Cheson Criteria for Non-DLBCL PopulationScreening up to disease progression or death, whichever occurs first (up to approximately 2.75 years)

Time from the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse or death from any cause (PFS), as assessed by the investigator for the subgroup of participants with a best overall response of CR or PR. For participants achieving a response who did not experience disease progression, relapse, or died prior to the time of the analysis, the DOR was censored on the date of last disease assessment.

Progression Free Survival, as Assessed by Investigator Using Cheson Criteria for DLBCL PopulationScreening up to disease progression or death, whichever occurs first (up to approximately 2.75 years)

Time from date of first dose of study drug (Day 1) to the first occurrence of progression or relapse, or death from any cause while in the study, as assessed by the investigator. If a participant did not experience progressive disease or death, PFS was censored on the day of the last tumor assessment. If a post-baseline assessment was not available, PFS was censored on Day 1.

Progression Free Survival, as Assessed by Investigator Using Cheson Criteria for Non-DLBCL PopulationScreening up to disease progression or death, whichever occurs first (up to approximately 2.75 years)

Time from date of first dose of study drug (Day 1) to the first occurrence of progression or relapse, or death from any cause while in the study, as assessed by the investigator. If a participant did not experience progressive disease or death, PFS was censored on the day of the last tumor assessment. If a post-baseline assessment was not available, PFS was censored on Day 1.

Relative Dose Intensity of Polatuzumab Vedotin (Ratio of the Amount of Drug Actually Administered to the Amount Planned) for Non-DLBCL Population6 months

Relative dose intensity (DI) was defined as the ratio of the amount of a drug actually administered (actual DI) to the amount planned (planned DI) for a fixed time period, expressed as a percentage.

Overall Survival for DLBCL PopulationScreening up to death due to any cause (up to approximately 6 years)

The time from the date of randomization to the date of death from any cause. For participants who did not die at the time of the analyses, OS was censored on the last date when the participants were known to be alive.

Overall Survival for Non-DLBCL PopulationScreening up to death due to any cause (up to approximately 6 years)

The time from the date of randomization to the date of death from any cause. For participants who did not die at the time of the analyses, OS was censored on the last date when the participants were known to be alive.

Trial Locations

Locations (11)

Hopital Henri Mondor, Unite Hemopathies lymphoides

🇫🇷

Creteil, France

Banner MD Anderson Cancer Center

🇺🇸

Greeley, Colorado, United States

The University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Northwest Cancer Specialists

🇺🇸

Portland, Oregon, United States

Oregon Health and Science University

🇺🇸

Portland, Oregon, United States

Washington University; Pediatrics

🇺🇸

Saint Louis, Missouri, United States

Willamette Valley Clinical Studies; Cancer Institute

🇺🇸

Springfield, Oregon, United States

Hopital Claude Huriez - CHU Lille; Service des maladies du sang

🇫🇷

Lille, France

Blue Ridge Cancer Care

🇺🇸

Roanoke, Virginia, United States

Centre Hospitalier Lyon Sud; Hematolgie

🇫🇷

Pierre Benite, France

Centre Henri Becquerel; Hematologie

🇫🇷

Rouen, France

Related Trials

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

RecruitingPhase 1
Shanghai Junshi Bioscience Co., Ltd.
Posted 11/18/2023
Updated 12/20/2024

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

RecruitingPhase 1
Beijing Mabworks Biotech Co., Ltd.
Posted 4/10/2023
Updated 11/20/2024

A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

RecruitingPhase 1
Beijing Mabworks Biotech Co., Ltd.
Posted 1/30/2024
Updated 3/15/2024

A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies

Not Yet RecruitingPhase 1
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Posted 9/24/2021
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy